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Table 1. Percentage reporting pretest and post-test counseling by source; respondents receiving diagnostic tests in 1992-1 993 (1 993 NI-IIS AID5 Knowledge and 
Attitudes Supplement). 
All respondents Increased risk group 
Yo 95% CI Ohs. % 95% CI Obs. 
Reporting pretest counseling 
Total 
Public source 
Private source 
~~ ~ ~ ~~ 
233 28.4 26.0-30.8 1759 37.7 
42.2 38.1-46.4 659 58.0 47.4-68.6 113 
20.8 1 8.1 -2 3.5 1100 21.9 12.1-3 1.6 120 
29.3-46.0 
Reporting post-test counseling 
Total 14.1 12.6-15.7 1759 27.4 20.4-34.5 233 
Public source 24.2 20.4-28.0 659 40.2 30.1-50.3 113 
Private source 8.6 7.0-1 0.2 1100 17.5 8.9-1 6.0 120 
Public sources: AIDS counseling and testing site, community health clinic, sexually transmitted disease clinic, family planning/prenatal clinic, public clinic, other 
clinic, drug treatment site, military site, immigration site, other location. Private sources: doctodHealth Maintenance Organization, hospital/emergency room, 
employer clinic, at home with nurse. Obs, observations. 
their tests; persons who used public programs reported 
receiving HIV counseling at a higher rate. On the other 
hand, the data reveal that a fairly high percentage of per- 
sons at increased risk had not been tested for HIV infec- 
tion, and additional effort is needed to identifjr this 
at-risk and untested sector of the population. 
Almost two-thirds of recent HIV diagnostic tests were 
obtained from private doctors and hospitals. This fact, 
coupled with the lower rates of counseling for private 
providers, underscores the importance of private practi- 
tioners being able to deliver appropriate HIV prevention 
messages, referrals and other seririces to persons tested 
for HIV 
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Finally, persons who are at increased risk for HIV infec- 
tion and reside outside of the central cities of metropoli- 
tan areas had significantly lower levels of recent diagnos- 
tic testing.This may be an important target area for HIV 
prevention programs. 
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j Two aberrant HIV-1 strains (HIV-lANT-,,, and HIV- 
1,,,,-,, 8J have been isolated from Cameroonian 
patients [1,2].These isolates had only 50% homology in 
the envelope region with other HIV-1 isolates and they 
were classified as group O. Since then additional HIV-1 
group O variants from Cameroonians living in France 
have been described and some of these group O sera 
have been shown to be unreactive in some commercial 
screening assays and can give indeterminate Western blot 
patterns [3]. Therefore studying the spread of these 
viruses is important in order to investigate whether strat- 
egies for blood screening and serodiagnosis need mocfifi- 
cation. 
Little is known on the spread of HIV-1 group O viruses 
in Africa. Studies among HIV-infected individuals from 
different African countries using an enzyme-linked 
immunosorbent assay (ELISA) based on the V3 peptide 
fiom ANT-70 and confirmation by a specific ANT-70 
Western blot indicate that HIV-1 group O infection is 
I 
present in Cameroon, Gabon and Nigeria, [4,5]. 
Sequence data on a limited number of samples have con- 
firmed that this strategy can lead to the identification of 
HIV-1 viruses from group O [6]. 
In this repoi? we show serological evidence that group O 
infection is also present in three different West Mican  
countries. We tested sera from Senegal, Niger and Togo. 
Senegal is situated at the tip of West Africa, Niger is a 
Sahelian country close to Cameroon but the main eco- 
nomic road is from Abidjan (Côte d'Ivoire) and the 
exchanges between Cameroon and Niger are very lim- 
ited.Togo is a small country bordering the sea and close 
to two important economic countries, Nigeria and Côte 
d'Ivoire. 
In 1990, 1184 prostitutes from Niger were tested for 
HIV-1 and HIV-2 infection. The overall prevalence was 
11.2% [84% (n = 113) were HIV-1-positive, 14% 
(n = 18) were HIV-Zpositive and 2% (n = 3) were posi- 
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tive for both HIV-1 and HIV-21. All HIV-positive sera 
were ELISA-positive and confirmed by Western blot 
with antibodies to a t  least two. envelope proteins. The 
HIV-positive sera from this survey were screened for 
antibodies to group O. A total of 2235 sera of Senegalese 
origin were tested for HIV-1 group O antibodies (SOS 
HIV-1,248 HIV-2,31 HIV-1 and HIV-2,40 indetermi- 
nate and 1108 HIV-negative). The sera were collected 
from prostitutes, pregnant women, sexually transmitted 
disease patients and AIDS patients from different regions 
in Senegal. Among the negative sera, 164 were collected 
between 1989 and 1994 from patients with clinical 
symptoms ofAIDS.The indeterminate sera were selected 
on the basis of a positive reaction in Genelavia niixt 
ELISA (Diagnostics Pasteur, Marnes-la-Coquette 
France), negative in the Clonatec (Paris, France) ELISA 
and indeterminate Western blot patterns (i.e., absence of 
antibodies to the envelope proteins). From Togo, a total 
of 878 sera (650 HIV-positive and 228 HIV-negative) 
collected between 1993 and 1995 in Lome, the capital 
city, were screened. 
All these sera were tested for group O antibodies with an 
improved ELISA using a combination of V3 peptides 
from ANT-70 and MVP-5180 (research product; Inno- 
genetics NV, Antwerp, Belgium). Sera reactive by 
ELISA were retested in a line immunoassay (LIA), in 
which different biotinylated V3 peptides - consensus, 
Mal,ANT-70,VI 686 (a Gabonese HIV-1 group O iso- 
late [6] and MVP-5180 - were applied as a streptavidin 
complex in parallel lines on nylon strips (research prod- 
uct; Innogenetics NV). Samples reactive in ELISA and 
LIA were also retested by Western blot for the presence 
of antibodies to gp120 of HIV-1ANT-7,1, as previously 
described [4]. 
In Niger, two HIV-1-positive sera were reactive inV3 
ELISA and reacted in LIA strongly and exclusively with 
the group O V3 peptides. The sera also reacted with 
gp120 of ANT-70 by Western blot which clearly con- 
firms the presence of antibodies to HIV-1 group O.The 
two prostitutes were both Nigerians. In Senegal, for one 
serum a similar reaction pattern was observed.The seruni 
was from an asymptomatic Senegalese women aged 19 
years with antibodies to HIV-1. In the samples from 
Togo, one HIV-positive serum had antibodies exclusively 
reactive with HIV-1 group O V 3  peptides in LIA and 
also reacted with the gp120 ofANT-70 by Western blot. 
t 
Our data show preliminary serological evidence that 
HIV-1 group O infection is not restricted to Cameroon 
or neighbouring countries, such as Gabon and Nigeria, 
but can also be found in West Africa, even in the most 
extreme west African country, Senegal. Compared to 
Camcroon, where a prevalence of 2% lias been reported 
[7], our results suggest that the prevalence of HIV-1 
group O infection is very low in West Africa.The spread 
of these viruses should be further examined to investi- 
gate whether their prevalence increases and to find out 
whether strategies for blood screening and serodiagnosis 
need modification. 
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Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users relative to 
homosexual men 
The interesting study by Spijkernian et 02. [l] identified a 
higher incidence of syncytium-inducing (SI) phenotype 
expected that progression to AIDS and rate of CD4 
decline are niore rapid in honiosexuai nien than in IDU. 
in homosexual nien compared with injecting drug users 
a switch in HIV-1 phenotype. If homosexual men have a 
higher incidence of SI phenotype then it might be 
(IDU) and confirmed the faster rate Of CD4 after Evidence from other studies for faster rates of 
sion to AIDS among homosexual nien than among IDU, 
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